TOPICS
What are CAR T-cells? | Clinical Trials | Comments
TOPIC Search: PubMed | CART-specific | News and Reports
Chimeric Antigen Receptor (CAR) enhanced T-cells are lymphocytes enhanced to have cancer-killing ability. These cells with cancer fighting potential are taken from our body and then engineered to bind to a universally expressed protein on the tumor cell, such as cd19, but also cd20 and cd22 at this time.
CAR T-cells can persist and expand in the body where the cells act like "living drug" - combining the specificity of antibodies with the killing power of t-cells. Efficacy seems dependent on the ability of the enhanced cells to expand and persist in the body after infusion into the patients. More
Engineered T-cells in clinical-phase testing
Anti-Cd19 CAR T-cell therapy
(adoptive t-cell immunotherapy targeting cd19 on mature b-cells) Find trials
Chimeric antigen receptor (CARs) T-cells
(targeting cd19, cd20, cd22 (adoptive t-cell therapy) Find Trials
News and Reviews
![]() |
Dec 2018 - Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. - PubMed - NCBI http://bit.ly/2GcI2sC |
![]() |
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions. http://bit.ly/2yAREcL
|
![]() |
Brewing T-cell therapies for leukemia and lymphoma - VJHemOnc http://bit.ly/2ASFmNc |
![]() |
About Fully human CD19-specific chimeric antigen receptors for T-cell therapy http://bit.ly/2gTbQi5
|
![]() |
JCO 2017: Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels http://bit.ly/2ueiDH0 (full text)
|
![]() |
2017
|
![]() |
*Targeted Onc 2016:
|
![]() |
New study reveals CAR T cells
|
![]() |
Anti-CD19 CAR T cells preceded by low-dose chemo to induce remissions of advanced lymphoma. | 2016 ASCO Annual http://bit.ly/1XVVzoa
|
![]() |
2016 Blood Journal
|
![]() |
2016: Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies -
|
![]() |
|
![]() |
Review article: Dec 2015:
|
![]() |
NEJM, Oct 2014
|
![]() |
J Clin Onc 2014:
|
![]() |
OncoTherapy Network
|
![]() |
News Medical 2013:
|
![]() |
* Helio 2013:
|
![]() |
* NIH 2013:
|
![]() |
The Promising Path for CAR Immunotherapy - OncologyTube
|
![]() |
ASH :2013
|
![]() |
ASH Paper, 2013:
|
![]() |
The Promising Path for CAR Immunotherapy - OncologyTube http://bit.ly/1aEpxkm |
![]() |
AACR 2013: Dr. Carl H. June, who was named one of Fast Company’s Most Creative People of 2013, spoke at this year’s Annual Meeting. Watch the free webcast of his talk,
|
What are Chimeric Antigen Receptor T-cells (CAR T-cells)?
ImedexCME video: David Porter: University of PA - CARs - A Living drug
Porter: presentation - CART Therapy for CLL - YouTubeAn antigen is any distinctive shape (such as a protein) that can be recognized by the immune system as a binding point - like a key that fits only one type of lock.
To make CAR T-cells cancer-fighting t-cells are first collected from the patient, then modified to recognize an antigen binding site on the cancer cells, and then put back into the patient.Remarkably, once put back into the patient the "programmed" t-cells can expand in number and persist for a long time and are capable of destroying any cells that have the target antigen.
We might think of this exciting technology as a way to modify t-cells to work similar to monoclonal antibody therapy (such as Rituxan that binds to cd20) - but with more potency and persistence - using live cells that can persist in the body ... instead of antibodies (proteins) that have are active for a limited time.
A more technical description:
"Chimeric antigen receptors (CARs) usually combine the antigen binding site of a monoclonal antibody with the signal activating machinery of a T cell, freeing antigen recognition from major histocompatibility complex restriction and thus breaking one of the barriers to more widespread application of cellular therapy.Similar to treatment strategies employing monoclonal antibodies, T cells expressing CARs are highly targeted, but additionally offer the potential benefits of active trafficking to tumor sites, in vivo expansion and long term persistence. Furthermore, gene transfer allows the introduction of countermeasures to tumor immune evasion and of safety mechanisms.
Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107373/
return to top
Reports and Background
Search Euro PubMed
![]() |
Axicabtagene Ciloleucel (Kite CAR t-cell therapy targeting cd19)
|
![]() |
Advanced Clinical Cell Processing Technologies for Adoptive Memory T Cell Therapy
|
![]() |
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Leukemia and Lymphoma Society http://bit.ly/1Lx2Lyc |
![]() |
ASH: T Cells Expressing CD19-Specific Chimeric Antigen Receptors Inhibited By
|
![]() |
Recommended
|
![]() |
BIG NEWS - Phila Business Journal 2014:
|
Technical background and overview
![]() |
Gene Therapy: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 http://1.usa.gov/1nNtvQI
|
![]() |
Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells http://1.usa.gov/1l3OugS
|
Clinical Reports and Discussions of Same
![]() |
The ASCO Post Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas http://bit.ly/KXVaPV
|
![]() |
April 2013: Gene Transfer Therapy Is Producing Prolonged Remissions in Patients with Advanced Leukemia
|
![]() |
Regarding Tumor Response to Modified Autologous T Cells NEJM
|
![]() |
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia http://www.nejm.org/doi/full/10.1056/NEJMoa1215134 |
![]() |
Video: Brian Koffman interview with Dr. Wierda
|
Technical Background
![]() |
Chimeric Antigen Receptor (CAR)-Engineered Lymphocytes for Cancer Therapy http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107373/
|
![]() |
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors
|
return to top
Clinical Trials
![]() |
anti-CD-19 directed engineered t-cells (CART19) (updated query) |